الاعتلال الكلوي الغشائي عند فشل العلاج المثبط للمناعة من الخط الثاني

References

DOI: 10.1016/j.kint.2021.05.015

Patients who did not respond to rituximab or cyclophosphamide should have a consultation with an expert center.

These centers may choose experimental therapies (bortezomib, anti-CD38 therapy, and belimumab) or a higher dose of conventional immunosuppressive therapy.